Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

J Am Coll Nutr. May-Jun 2016;35(4):346-53. doi: 10.1080/07315724.2015.1021057. Epub 2015 Jul 9.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disorder related to inflammation. Coenzyme Q10 (CoQ10) is a natural compound that has recently been considered as an anti-inflammatory factor. In the current study we aimed to evaluate the effects of CoQ10 supplementation on liver enzymes, inflammation status, and adipokines in patients with NAFLD.

Methods: Forty-one subjects with NAFLD participated in the current randomized, double-blind, placebo-controlled trial. The participants were randomly divided into 2 groups: one group received CoQ10 capsules (100 mg once a day) and the other received placebo for 12 weeks. Blood samples of each patient were taken before and after the 12-week intervention period for measurement of liver aminotransferases, inflammatory biomarkers, and adipokines (adiponectin and leptin).

Results: Taking 100 mg CoQ10 supplement daily resulted in a significant decrease in liver aminotransferases (aspartate aminotransferase [AST] and gamma-glutamyl transpeptidase [GGT]), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor α, and the grades of NAFLD in the CoQ10 group in comparison to the control group (p < 0.05). In addition, patients who received CoQ10 supplement had higher serum levels of adiponectin (p = 0.016) and considerable changes in serum leptin (p = 0.053). However, no significant changes occurred in serum levels of interleukin-6 in both groups.

Conclusion: The present study suggested that CoQ10 supplement at a dosage of 100 mg could be effective for improving the systemic inflammation and biochemical variables in NAFLD.

Keywords: adipocytokines; coenzyme Q10 (CoQ10); inflammation; nonalcoholic fatty liver disease (NAFLD).

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipokines / blood*
  • Adiponectin / blood
  • Adult
  • Aspartate Aminotransferases / blood
  • Biomarkers / blood*
  • Body Mass Index
  • C-Reactive Protein / analysis
  • Dietary Supplements
  • Double-Blind Method
  • Female
  • Humans
  • Inflammation / blood*
  • Leptin / blood
  • Liver / enzymology*
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Placebos
  • Tumor Necrosis Factor-alpha / blood
  • Ubiquinone / administration & dosage
  • Ubiquinone / analogs & derivatives*
  • gamma-Glutamyltransferase / blood

Substances

  • Adipokines
  • Adiponectin
  • Biomarkers
  • Leptin
  • Placebos
  • Tumor Necrosis Factor-alpha
  • Ubiquinone
  • C-Reactive Protein
  • gamma-Glutamyltransferase
  • Aspartate Aminotransferases
  • coenzyme Q10